- Published on 07 April 2014
Oticon Medical announced on March 25th that the company has entered into a partnership with Bo Håkansson, PhD, Professor at Chalmers University of Technology, Gothenburg, Sweden, for the future commercialization of the active transcutaneous Bone Conduction Implant (BCI).
“We will build on Prof. Håkansson’s leading-edge work with the proven strengths of our Ponto System including the powerful and efficient Inium signal processing platform and wireless capabilities,” says Oticon Medical President Jes Olsen.
The new project will use the proprietary BEST transducer that is less than half the size of transducers found in comparable products. The BEST transducer provides the highest efficiency and smallest volume, making surgery straightforward and the anatomical coverage high.
“I look very much forward to the cooperation with Oticon Medical and the teams in Gothenburg, Copenhagen and Nice that were instrumental in bringing the Ponto System to market. Their commitment to develop solutions for better patient outcomes and Oticon Medical’s global distribution structure and financial strength will certainly fuel the future industrialization and commercialization of this BCI project,” observes Prof. Håkansson.
In the future, there will be a need for both the current percutaneous Ponto System and the active transcutaneous BCI project to ensure high fidelity sound quality to all types of patients with conductive and mixed hearing losses as well as single-sided deafness. “The two complementary solutions in the future Oticon Medical portfolio will give professionals and patients an option to choose the most optimal solution for the individual patient - based on type of hearing loss, age, reversibility wishes and cosmetics” says Olsen.
Read more on Prof. Bo Håkansson and the BCI project here.
Source: Oticon Medical